$1.03
-0.02 (-1.90%)
Open$1.04
Previous Close$1.05
Day High$1.08
Day Low$1.02
52W High$2.25
52W Low$0.49
Volume—
Avg Volume141.3K
Market Cap97.63M
P/E Ratio—
EPS$-0.48
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,001.0% upside
Current
$1.03
$1.03
Target
$31.94
$31.94
$22.24
$31.94 avg
$42.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.40M | 13.64M | 13.89M |
| Net Income | -704,326 | -740,627 | -795,931 |
| Profit Margin | -4.6% | -5.4% | -5.7% |
| EBITDA | -1,183,474 | -997,072 | -1,062,628 |
| Free Cash Flow | -738,508 | -859,127 | -679,392 |
| Rev Growth | +4.1% | +16.3% | -0.4% |
| Debt/Equity | 0.22 | 0.30 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |